ZDA
ALNY icon

Zweig-DiMenna Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Zweig-DiMenna Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,800
Closed -$255K – 248
2014
Q1 		$255K Buy
+3,800
New +$294K 0.02% 155

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Zweig-DiMenna Associates's ALNY Position: Q2 2014 in Review

Zweig-DiMenna Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 3,800 shares — an estimated $255K sold.

Zweig-DiMenna Associates first reported a position in ALNY in Q1 2014 and held it in 1 quarter. The position peaked at $255K in Q1 2014. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Zweig-DiMenna Associates reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 3,800 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $255K.
  • Zweig-DiMenna Associates first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Alnylam Pharmaceuticals position peaked at $255K in Q1 2014.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2014, filed 12 Aug 2014.